Key Points
- CEO Hans Schambye sold 700 shares on Jan. 2 at an average price of $21.38 for $14,966, reducing his ownership by 13.01% to 4,682 shares valued at about $100,101 (SEC filing).
- Stock and financial context: GLTO trades near its 50‑day moving average (~$21.20) with a market cap of ~$34.94M and a negative P/E; the company reported quarterly EPS of -$2.36 and analysts carry a mixed view (consensus "Hold" with a $36 price target, one Buy and one Sell).
Galecto, Inc. (NASDAQ:GLTO - Get Free Report) CEO Hans Schambye sold 700 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $21.38, for a total transaction of $14,966.00. Following the sale, the chief executive officer directly owned 4,682 shares in the company, valued at $100,101.16. The trade was a 13.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Galecto Stock Performance
GLTO stock opened at $21.84 on Wednesday. The company has a fifty day moving average price of $21.20 and a 200-day moving average price of $10.48. Galecto, Inc. has a 52-week low of $2.01 and a 52-week high of $38.33. The company has a market capitalization of $34.94 million, a P/E ratio of -1.80 and a beta of 1.42.
Galecto (NASDAQ:GLTO - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($2.36) earnings per share for the quarter. As a group, sell-side analysts forecast that Galecto, Inc. will post -15.91 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Galecto
Several hedge funds and other institutional investors have recently modified their holdings of GLTO. Connective Capital Management LLC bought a new position in shares of Galecto in the 3rd quarter worth $100,000. Virtu Financial LLC bought a new stake in Galecto during the 3rd quarter valued at $49,000. Finally, Two Sigma Investments LP acquired a new position in Galecto during the third quarter worth $76,000. Institutional investors own 14.20% of the company's stock.
Analyst Upgrades and Downgrades
GLTO has been the topic of a number of analyst reports. Wall Street Zen raised shares of Galecto from a "sell" rating to a "hold" rating in a research note on Saturday, December 6th. Guggenheim lifted their price objective on Galecto from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, December 8th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Galecto in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $36.00.
View Our Latest Research Report on GLTO
Galecto Company Profile
(
Get Free Report)
Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.
Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
